GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) » Definitions » Volatility

Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Volatility : 76.64% (As of Apr. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biohaven Pharmaceutical Holding Co Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-04-26), Biohaven Pharmaceutical Holding Co's Volatility is 76.64%.


Competitive Comparison of Biohaven Pharmaceutical Holding Co's Volatility

For the Biotechnology subindustry, Biohaven Pharmaceutical Holding Co's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biohaven Pharmaceutical Holding Co's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biohaven Pharmaceutical Holding Co's Volatility distribution charts can be found below:

* The bar in red indicates where Biohaven Pharmaceutical Holding Co's Volatility falls into.



Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Biohaven Pharmaceutical Holding Co Volatility Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Business Description

Traded in Other Exchanges
N/A
Address
C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
Executives
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark officer: VP, Chief Accounting Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Elyse Stock officer: Chief Medical Officer 215 CHURCH STREET NEW HAVEN CT 06510
James Engelhart officer: Chief Financial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten officer: Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Declan Doogan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs director, 10 percent owner 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Kishan Mehta director 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Jones William A Jr officer: CCO-Migraine & Common Disease NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Kimberly Gentile officer: VP of Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Robert Berman officer: Chief Medical Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John Tilton officer: Chief Commercial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054